Nivolumab is a type of immunotherapy drug that is administered intravenously (into a vein) in the treatment of several types of cancer. It works by blocking the action of a protein called PD-1, which helps to keep the immune system from attacking cancer cells. By blocking PD-1, nivolumab allows the immune system to recognize and destroy cancer cells more effectively.

According to the information provided, nivolumab is typically given by a healthcare professional in a hospital or clinic setting. The drug is usually administered slowly, over the course of 30 minutes to an hour, and treatment may be repeated every 2 weeks or according to a healthcare professional's recommendation.

It is important to note that the exact dosage and administration of nivolumab may vary depending on several factors, including the patient's weight, kidney function, and the type and stage of cancer being treated. Additionally, nivolumab may be used alone or in combination with other cancer treatments, such as chemotherapy or radiation therapy.

Patients receiving nivolumab should be monitored closely for side effects, which can include fatigue, rash, diarrhea, itching, and joint pain. In rare cases, more serious side effects, such as severe allergic reactions or immune-related adverse events, may occur.

In summary, nivolumab is an intravenous immunotherapy drug used in the treatment of various types of cancer. It is typically administered every 2 weeks by a healthcare professional in a hospital or clinic setting. The exact dosage and administration may vary depending on several factors, and patients should be monitored closely for side effects.

Sources:

* <https://www.drugpatentwatch.com/p/biologics/ingredient/nivolumab>
* <https://www.ncbi.nlm.nih.gov/books/NBK567801/>
* <https://www.cancerresearchuk.org/about-cancer/treatment/drugs/nivolumab>